27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Auris Medical Holding Ltd (NASDAQ:EARS) has announced additional preclinical data in a primary human nasal airway epithelium model from its Bentrio (AM-301) nasal spray for COVID-19.
- AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.
- The manuscript of the preclinical data is available here.
- Prophylactic treatment with AM-301 was protective against SARS-CoV-2 infection. The daily application of the product starting 10 minutes before inoculation led to a 2-log (99%) reduction in viral titer by Day 4 compared to controls.
- Inserts that received the product daily, starting 24 or 30 hours after viral infection, also had a lower viral titer, corresponding to a 12- or 14-fold lower TCID50 at the end of the treatment.
- The time profile of SARS-CoV-2 infection was significantly decelerated compared to controls both in the case of prophylactic treatment and in the case of mitigation treatment starting 24 or 30 hours post-infection.
- Price Action: EARS shares are up 1.61% at $3.22 during the market session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!